Literature DB >> 1672248

NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection.

A S Fauci1, S M Schnittman, G Poli, S Koenig, G Pantaleo.   

Abstract

An understanding of the immunopathogenic mechanisms of infection with human immunodeficiency virus (HIV) is fundamental in developing successful approaches to designing effective therapeutic and vaccine strategies. In this regard, we have investigated the mechanisms by which HIV inserts itself into the human immune system and uses the elaborate cytokine network to its own replicative advantage. We have also shown that the burden of HIV in CD4+ T cells is directly associated with a decline in this cell population in vivo and a progression to disease. Mononuclear phagocytes may play a role in the pathogenesis of HIV infection by serving as reservoirs of the virus. Of note is the fact that monocytes in the peripheral blood of HIV-infected individuals are rarely infected in vivo, whereas infected-tissue macrophages may play a role in organ-specific HIV-related pathogenesis. The role of HIV-specific humoral and cell-mediated immunity in HIV infection is not well understood. However, fine specificity of responses against HIV have been delineated in some in-vitro systems. It is unclear why these responses, particularly HIV-specific cytolytic T-cell responses, diminish over the course of infection and are unable to contain progression of infection.

Entities:  

Mesh:

Year:  1991        PMID: 1672248     DOI: 10.7326/0003-4819-114-8-678

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  54 in total

1.  HIV prevalence among foreign- and US-born clients of public STD clinics.

Authors:  Nina T Harawa; Trista A Bingham; Susan D Cochran; Sander Greenland; William E Cunningham
Journal:  Am J Public Health       Date:  2002-12       Impact factor: 9.308

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors.

Authors:  Louis Alexander; Sharon Zhang; Brian McAuliffe; David Connors; Nannon Zhou; Tao Wang; Michele Agler; John Kadow; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

4.  Lymphocyte subset diversity in idiopathic CD4+ T lymphocytopenia.

Authors:  P Tassinari; L Deibis; N Bianco; G Echeverría de Pérez
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

Review 5.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

6.  Contact of human immunodeficiency virus type 1-infected and uninfected CD4+ T lymphocytes is highly cytolytic for both cells.

Authors:  M Heinkelein; S Sopper; C Jassoy
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.

Authors:  D Weissman; G Poli; A Bousseau; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

8.  Changes in natural immunity during the course of HIV-1 infection.

Authors:  B G Brenner; C Gryllis; M Gornitsky; M A Wainberg
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Thalidomide inhibits the replication of human immunodeficiency virus type 1.

Authors:  S Makonkawkeyoon; R N Limson-Pobre; A L Moreira; V Schauf; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  Secretory immunoglobulins in serum from human immunodeficiency virus (HIV)-infected patients.

Authors:  C Vincent; G Cozon; M Zittoun; M Mellquist; M D Kazatchkine; C Czerkinsky; J P Revillard
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.